339 related articles for article (PubMed ID: 25929767)
1. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide.
Ko C; Park WJ; Park S; Kim S; Windisch MP; Ryu WS
Antivir Ther; 2015; 20(8):835-42. PubMed ID: 25929767
[TBL] [Abstract][Full Text] [Related]
2. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
Wang XJ; Hu W; Zhang TY; Mao YY; Liu NN; Wang SQ
Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
[TBL] [Abstract][Full Text] [Related]
4. NTCP-Reconstituted In Vitro HBV Infection System.
Sun Y; Qi Y; Peng B; Li W
Methods Mol Biol; 2017; 1540():1-14. PubMed ID: 27975303
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide.
Okuyama-Dobashi K; Kasai H; Tanaka T; Yamashita A; Yasumoto J; Chen W; Okamoto T; Maekawa S; Watashi K; Wakita T; Ryo A; Suzuki T; Matsuura Y; Enomoto N; Moriishi K
Sci Rep; 2015 Nov; 5():17047. PubMed ID: 26592202
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
[TBL] [Abstract][Full Text] [Related]
8. Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication.
Qiao L; Sui J; Luo G
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232184
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
Nio Y; Akahori Y; Okamura H; Watashi K; Wakita T; Hijikata M
Biochem Biophys Res Commun; 2018 Jun; 501(3):820-825. PubMed ID: 29723527
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B.
Zhao K; Liu S; Chen Y; Yao Y; Zhou M; Yuan Y; Wang Y; Pei R; Chen J; Hu X; Zhou Y; Zhao H; Lu M; Wu C; Chen X
Emerg Microbes Infect; 2018 Nov; 7(1):186. PubMed ID: 30459339
[TBL] [Abstract][Full Text] [Related]
12. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
13. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
[TBL] [Abstract][Full Text] [Related]
14. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
[TBL] [Abstract][Full Text] [Related]
15. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
Li J; Zong L; Sureau C; Barker L; Wands JR; Tong S
J Virol; 2016 Sep; 90(18):8302-13. PubMed ID: 27384660
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 6 inhibits HBV entry through NTCP down regulation.
Bouezzedine F; Fardel O; Gripon P
Virology; 2015 Jul; 481():34-42. PubMed ID: 25765005
[TBL] [Abstract][Full Text] [Related]
17. N-Linked Glycosylation Is Not Essential for Sodium Taurocholate Cotransporting Polypeptide To Mediate Hepatitis B Virus Infection
Lee J; Zong L; Krotow A; Qin Y; Jia L; Zhang J; Tong S; Li J
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793953
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression.
Tsukuda S; Watashi K; Iwamoto M; Suzuki R; Aizaki H; Okada M; Sugiyama M; Kojima S; Tanaka Y; Mizokami M; Li J; Tong S; Wakita T
J Biol Chem; 2015 Feb; 290(9):5673-84. PubMed ID: 25550158
[TBL] [Abstract][Full Text] [Related]
19. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
Blanchet M; Sureau C; Labonté P
Antiviral Res; 2014 Jun; 106():111-5. PubMed ID: 24717262
[TBL] [Abstract][Full Text] [Related]
20. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
